leaderobot.com reports on Exin Therapeutics' live-mouse surgery experiment

On November 6, 2026, leaderobot.com reported on Exin Therapeutics' live-mouse surgery experiment.

The focus in reading this report is to consider separately the research results themselves, control interfaces, safety-related decisions and laboratory operations, rather than treating all robot-assisted research as one category. Related coverage by this newspaper includes QuEra demonstrates Anthropic’s “MCP for physical AI,” with a 99% error recovery success rate, which covered a demonstration of a system proposed by Anthropic; Binghamton University research team publishes study on safety of AI-powered robots, which addressed the safety of AI-powered robots; and Warp Sciences to build robotics-based drug discovery research platform, raises $215 million, which covered an automation platform for drug discovery research. These are separate reports and do not demonstrate a technical connection to the current experiment or shared operating conditions. Therefore, rather than assessing this case as a general advance in research automation, it is necessary to examine how roles are divided between people and systems in the individual experiment. Having a control mechanism in place and being able to safely hand over an experiment in the event of an anomaly are separate issues; the related reports cannot fill in details about this case’s design or procedures. Nor can safety or recovery performance demonstrated in different research settings be applied as-is to other equipment or experiments. What we should examine next includes the experimental procedures, how the equipment and models are connected, handover when the system is stopped, and whether independent verification was conducted. However, the information provided is insufficient for a comprehensive assessment of these points. See the original source for details of what was reported.